Fong Clinical Risk Score for Colorectal Cancer Recurrence
Predicts outcome after hepatic resection for colorectal liver metastases. Five clinical risk factors identify patients most likely to benefit from resection.
Score interpretation
→ Fong 0: No risk factors. 5-year survival ~60%. Proceed with hepatic resection if technically feasible and patient is fit. Excellent surgical candidate.
→ Fong 1–2: 5-year survival ~40–47%. Good surgical candidates. Hepatic resection recommended if R0 achievable. Discuss perioperative chemotherapy (FOLFOX).
→ Fong 3: 5-year survival ~20–25%. Intermediate-risk group. Hepatic resection may still be beneficial; multi-disciplinary team (MDT) review essential. Consider neoadjuvant chemotherapy.
→ Fong 4–5: 5-year survival <15%. High-risk group. Hepatic resection offers limited survival benefit. Discuss systemic chemotherapy as primary treatment; consider SIRT/TACE; palliative intent.
Interpretation bands for the Fong Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- CRASH Score for Chemotherapy Risk Assessment in Elderly Patients · Oncology
- Ann Arbor Staging System for Lymphoma · Oncology
- Rai Staging System for CLL · Oncology
- Follicular Lymphoma International Prognostic Index (FLIPI) · Oncology
- International Staging System for Multiple Myeloma (ISS) · Oncology
- CISNE Score for Febrile Neutropenia · Oncology
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Zoledronic Acid · IV Bisphosphonate
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.